Sign In
Buy MGNX
$4.69
+0.110 (+2.40%)
At Close: Jun 23, 2026
Q2 2020 Earnings Forecast for MacroGenics Inc Issued By SVB Leerink (NASDAQ:MGNX)
07:05am, Thursday, 25'th Jun 2020
MacroGenics Inc (NASDAQ:MGNX) – Stock analysts at SVB Leerink boosted their Q2 2020 EPS estimates for shares of MacroGenics in a research note issued on Monday, June 22nd. SVB Leerink analyst J. Cha
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 23)
ACADIA Pharmaceuticals Inc...
MacroGenics Announces Presentation of Preclinical Data at the 2020 AACR Annual Meeting
01:00pm, Monday, 22'nd Jun 2020
Rockville, MD, June 22, 2020 -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal.
Hedge Fund Manager in Sweden Reveals His Best Pharma Bets - BNN Bloomberg
02:14pm, Friday, 19'th Jun 2020
The founding partner at a Swedish hedge fund that’s delivered more than 700% over the past decade is a big fan of Roche Holding AG and thinks there’ll be about 10 Covid-19 vaccines in a year’s t
MacroGenics Inc (NASDAQ:MGNX) Shares Acquired by Massachusetts Financial Services Co. MA
08:00am, Thursday, 18'th Jun 2020
Massachusetts Financial Services Co. MA grew its position in MacroGenics Inc (NASDAQ:MGNX) by 18.8% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commiss
MacroGenics Appoints Dr. Stephen Eck As Chief Medical Officer
11:30am, Tuesday, 16'th Jun 2020
MacroGenics, Inc. (MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announce
MacroGenics Inc (NASDAQ:MGNX) Shares Bought by Citigroup Inc.
06:02am, Tuesday, 16'th Jun 2020
Citigroup Inc. increased its holdings in shares of MacroGenics Inc (NASDAQ:MGNX) by 7.1% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commissio
MacroGenics Announces Margetuximab Granted Orphan Drug Designation In The US For Gastric Cancer
11:30am, Friday, 05'th Jun 2020MacroGenics Announces Margetuximab Granted Orphan Drug Designation in the U.S. for Gastric Cancer
11:30am, Friday, 05'th Jun 2020
MacroGenics, Inc. (MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announce
MacroGenics, Inc. (MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announce
